21-hydroxylase deficiency classification: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{{Congenital adrenal hyperplasia due to 21-hydroxylase deficiency}} | |||
{{21-hydroxylase deficiency}} | |||
{{CMG}}; '''Associate Editor-In-Chief:''' {{MJ}} | {{CMG}}; '''Associate Editor-In-Chief:''' {{MJ}}{{AAM}} | ||
==Overview== | ==Overview== | ||
21-hydroxylase deficiency may be classified | Congenital adrenal hyperplasia due to 21-hydroxylase deficiency may be classified into two subtypes based on severity and time of onset: Classical and non-classical forms. | ||
== | ==classification== | ||
21- | 21-hydroxilase deficiency my be classified by clinical manifestations in to two forms: | ||
*Classical form, most severe form of 21-hydroxylase deficiency, presents during the | *Classical form, most severe form of 21-hydroxylase deficiency, presents during the neonatal period and early infancy. The classical form can be classified in to two subtypes: | ||
** | **classical salt wasting | ||
** | **Classical non-salt wasting | ||
*Non- | *Non-classical form or late-onset 21-hydroxylase deficiency, presents later during the adolescence period.<ref name="pmid10857554">{{cite journal |vauthors=White PC, Speiser PW |title=Congenital adrenal hyperplasia due to 21-hydroxylase deficiency |journal=Endocr. Rev. |volume=21 |issue=3 |pages=245–91 |year=2000 |pmid=10857554 |doi=10.1210/edrv.21.3.0398 |url=}}</ref><ref name="pmid20823466">{{cite journal |vauthors=Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, Meyer-Bahlburg HF, Miller WL, Montori VM, Oberfield SE, Ritzen M, White PC |title=Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline |journal=J. Clin. Endocrinol. Metab. |volume=95 |issue=9 |pages=4133–60 |year=2010 |pmid=20823466 |pmc=2936060 |doi=10.1210/jc.2009-2631 |url=}}</ref> | ||
Revision as of 14:44, 22 April 2019
|
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency Microchapters |
|
Differentiating Congenital adrenal hyperplasia due to 21-hydroxylase deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
21-hydroxylase deficiency classification On the Web |
|
American Roentgen Ray Society Images of 21-hydroxylase deficiency classification |
|
Directions to Hospitals Treating Congenital adrenal hyperplasia due to 21-hydroxylase deficiency |
|
Risk calculators and risk factors for 21-hydroxylase deficiency classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Mehrian Jafarizade, M.D [2]Ahmad Al Maradni, M.D. [3]
Overview
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency may be classified into two subtypes based on severity and time of onset: Classical and non-classical forms.
classification
21-hydroxilase deficiency my be classified by clinical manifestations in to two forms:
- Classical form, most severe form of 21-hydroxylase deficiency, presents during the neonatal period and early infancy. The classical form can be classified in to two subtypes:
- classical salt wasting
- Classical non-salt wasting
- Non-classical form or late-onset 21-hydroxylase deficiency, presents later during the adolescence period.[1][2]
- ↑ White PC, Speiser PW (2000). "Congenital adrenal hyperplasia due to 21-hydroxylase deficiency". Endocr. Rev. 21 (3): 245–91. doi:10.1210/edrv.21.3.0398. PMID 10857554.
- ↑ Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, Meyer-Bahlburg HF, Miller WL, Montori VM, Oberfield SE, Ritzen M, White PC (2010). "Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline". J. Clin. Endocrinol. Metab. 95 (9): 4133–60. doi:10.1210/jc.2009-2631. PMC 2936060. PMID 20823466.